GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit

Core Insights - GT Biopharma, Inc. is a clinical stage immuno-oncology company focused on developing therapeutics based on its proprietary TriKE platform, which enhances the cancer-killing abilities of natural killer cells [1][3] - Michael Breen, the Executive Chairman and CEO, will participate in the Centurion One Capital 3rd Annual Bahamas Summit on October 28-29, 2025 [1] - The company will be available for one-on-one meetings at the conference, indicating an opportunity for potential investors to engage directly [2] Company Overview - GT Biopharma is dedicated to the development and commercialization of immuno-oncology therapeutic products utilizing the TriKE NK cell engager platform [3] - The company holds an exclusive worldwide license agreement with the University of Minnesota for the development and commercialization of therapies using TriKE technology [3] - For further information, the company directs interested parties to its website [3]